Search

Patients' considerations when choosing an orthodontist are influenced by many factors, including background, ethnicity, and location. Accordingly, this study aimed to identify factors influencing patients' considerations when selecting an orthodontist in both Malaysia and Taiwan. In total, 248 dental students from Taipei Medical University and 110 dental students from Manipal University College Malaysia were selected for this study. Participants' considerations when selecting an orthodontist were assessed using a questionnaire survey. The questionnaire collected data regarding participants' demographic characteristics and their preferences regarding clinical settings, orthodontist attributes, administrative systems, and the influence of social media. The gathered data were analyzed and compared using independent t -test, ANOVA, and chi-squared for both cohorts. The present results revealed significant differences between the Malaysian and Taiwanese participants with several variables, including orthodontist experience, recommendations, pain-free treatment procedures, treatment duration, friendly reception, sources of information about orthodontists, and preferred social media platforms. Notably, among the Taiwanese participants, "person responsible for treatment costs," was significantly correlated with the orthodontist's age, the orthodontist's work experience, information sources, travel distance, and content posted by orthodontists on social media. By contrast, among the Malaysian participants, this variable was correlated with the work experience of orthodontists. Significant differences were observed between the Malaysian and Taiwanese participants in terms of their considerations when choosing an orthodontist. Participant's gender significantly influenced orthodontist preferences among the Malaysian participants, whereas the individual responsible for treatment costs was identified to be the most crucial factor influencing the Taiwanese participants. [ABSTRACT FROM AUTHOR]

Trastuzumab given intravenously in combination with chemotherapy is standard of care for patients with early HER2-positive breast cancer (BC). Different randomised studies have shown equivalent efficacy of a subcutaneous injection into the thigh compared to the intravenous formulation. Other body regions for injection have not been investigated but might be more convenient for patients. After surgery, patients were randomised to receive either subcutaneous trastuzumab into the thigh or into the abdominal wall (AW). Patient preferences were evaluated using validated questionnaires (PINT). Primary objectives of this multicentre, non-blinded, randomised substudy of the GAIN-2 study were to investigate pharmacokinetics of the injection into the thigh versus AW and to determine patients' preferences of either administration site versus the previously received intravenous application. 226 patients were randomised and 219 patients (thigh: N = 110; AW: N = 109) formed the modified intent-to-treat (mITT). Overall, 83.5% (out of N = 182 with information about patients' preference) preferred subcutaneous over previous intravenous application or had no preference. Preference was similar between both administration sites (thigh: 80.6%; AW: 86.5; p = 0.322). Pharmacokinetic analysis included 30 patients. Geometric means of C max and AUC 0-21d were higher in thigh than in AW group (geometric mean ratio with body weight adjustment: C max : 1.291, 90%-CI 1.052–1.584; AUC 0-21d : 1.291, 90%-CI 1.026–1.626). Safety profile was in line with previous reports of subcutaneous trastuzumab. Subcutaneous trastuzumab into the thigh showed an approximately 30% higher bioavailability. Injections were well tolerated and preferred over intravenous administration. The subcutaneous injection into the thigh should remain the standard of care. • The bioavailability of subcutaneous trastuzumab was 30% higher when injected the thigh vs the abdominal wall. • Patients preferred subcutaneous over intravenous injection of trastuzumab. • Patient preference was comparable between abdominal wall or thigh subcutaneous injection. • There were no new safety signals for subcutaneous trastuzumab injection. [ABSTRACT FROM AUTHOR]

Copyright of Radiologia Brasileira is the property of Radiologia Brasileira and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)